Skip to main content
. 2019 Aug 5;10:865. doi: 10.3389/fphar.2019.00865

Figure 1.

Figure 1

H2 protects against lipopolysaccharide (LPS)-induced cardiac dysfunction. (A) Representative M-mode echocardiographic images at 6 h after LPS injection. (B–E) Quantification of left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), EF%, and FS% by echocardiography at 6 h after LPS injection (n = 10). **P < 0.01 vs Control, ## P < 0.01 vs LPS.